Nektar Therapeutics (NKTR) CEO Sells $4,640,814.77 in Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the transaction, the chief executive officer now owns 272,768 shares of the company’s stock, valued at approximately $15,190,449.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nektar Therapeutics (NASDAQ NKTR) traded up $1.85 during trading hours on Friday, hitting $56.90. 3,711,627 shares of the stock were exchanged, compared to its average volume of 1,710,505. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $57.83. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter in the previous year, the company posted ($0.32) earnings per share. Nektar Therapeutics’s quarterly revenue was up 321.2% compared to the same quarter last year. sell-side analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current year.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 0.9% in the second quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock valued at $395,330,000 after acquiring an additional 185,933 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Nektar Therapeutics by 3.0% in the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after acquiring an additional 401,914 shares during the last quarter. State Street Corp raised its stake in shares of Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after acquiring an additional 447,023 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Nektar Therapeutics by 87.8% in the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after acquiring an additional 1,556,352 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Nektar Therapeutics by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after purchasing an additional 12,730 shares during the last quarter. Institutional investors own 96.04% of the company’s stock.

A number of brokerages have commented on NKTR. Canaccord Genuity raised their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, November 13th. Canaccord Genuity Group raised their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Mizuho raised their price target on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Finally, J P Morgan Chase & Co restated a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $35.58.

WARNING: “Nektar Therapeutics (NKTR) CEO Sells $4,640,814.77 in Stock” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/15/nektar-therapeutics-nktr-ceo-sells-4640814-77-in-stock.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply